Defining Diffuse Large B-Cell Lymphoma Immunotypes by CD8+ T Cells and Natural Killer Cells

Area of Science:

• Oncology
• Immunology
• Bioinformatics

Background:

• Diffuse large B-cell lymphoma (DLBCL) has a poor prognosis.
• Gene expression profiles can reveal prognostic subtypes in DLBCL.
• Immune cell infiltration impacts DLBCL outcomes.

Purpose of the Study:

• To identify novel immune subtypes in DLBCL using gene expression data.
• To evaluate the prognostic significance of these immune subtypes.
• To develop a predictive model for DLBCL immune subtypes and identify potential therapeutic targets.

Main Methods:

• Immune subtypes were derived from CD8+ T cell and NK cell gene expression.
• Prognostic comparisons and pathway enrichment analyses were performed.
• Machine learning models were used for subtype prediction, and virtual screening identified potential drug targets.

Main Results:

• Two novel immune subtypes, inflamed (IS) and noninflamed (NIS), were identified.
• IS demonstrated higher immune cell levels and a better prognosis for immunotherapy compared to NIS.
• A 12-gene random forest model achieved an AUC of 0.948 for subtype prediction, and three small molecules targeting NIS biomarkers were identified.

Conclusions:

• Immune cells serve as crucial prognostic factors in DLBCL.
• A novel immune subtype classification can predict response to immune checkpoint blockade (ICB).
• A robust machine learning model and potential therapeutic small molecules were developed for DLBCL immune subtypes.